Cumulative Hemodynamic Response to Short-Term Treatment with Flosequinan (BTS 49465), a New Direct-Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure
- 30 June 1988
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 12 (1), 6-11
- https://doi.org/10.1097/00005344-198807000-00002
Abstract
Pharmacologic tolerance develops rapidly to the hemodynamic effects of many vasodilator drugs used in the treatment of congestive heart failure. We evaluated the responses to 3 days of therapy with a new long-acting vasodilator drug, flosequinan (BTS 49465), in 16 patients with severe chronic heart failure. On each of the 3 days, flosequinan (100 or 150 mg orally) produced marked increases in cardiac index and decreases in left ventricular filling pressure, mean right atrial pressure, and systemic vascular resistance (all p < 0.01) without significant changes in heart rate. Whereas the effects of flosequinan on right and left ventricular filling pressures on the first and third days were similar, cardiac index was higher and systemic vascular resistance was lower after the third dose than after the first dose of the drug, indicating the occurrence of a cumulative vasodilator effect on arterial resistance vessels. Since all hemodynamic changes persisted for longer than 24 h after each dose of the drug, the daily administration of flosequinan also produced a progressive improvement in the hemodynamic state recorded before each dose of the drug. These data indicate that pharmacologic tolerance does not develop to the effects of flosequinan during short-term therapy with the drug in patients with severe chronic heart failure. Instead, further hemodynamic improvement may occur because of a cumulative vasodilator effect that results from the drug's prolonged duration of action.Keywords
This publication has 20 references indexed in Scilit:
- Hemodynamic and Hormonal Response to Transdermal Nitroglycerin in Normal Subjects and in Patients With Congestive Heart FailureJournal of the American College of Cardiology, 1983
- Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure.Circulation, 1983
- Efficacy of prazosin in the management of chronic congestive heart failure: A 6-month randomized, double-blind, placebo-controlled studyThe American Journal of Cardiology, 1983
- Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.Circulation, 1983
- Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study.Circulation, 1983
- Effect of orally administered hydralazine on neurohumoral factors and hemodynamic response in aged patients with chronic congestive heart failure.Japanese Heart Journal, 1983
- Hemodynamic Characterization of Tolerance to Long-Term Hydralazine Therapy in Severe Chronic Heart FailureNew England Journal of Medicine, 1982
- Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy.Circulation, 1981
- Attenuation of Prazosin Effect on Cardiac Output in Chronic Heart FailureAnnals of Internal Medicine, 1979
- Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.Circulation, 1979